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Deep vein thrombosis (DVT) represents the formation of blood clots within the deep venous system. 
It is a common and dangerous disease in the most serious since clots can propagate from the deep 
veins leading to a fatal pulmonary embolus. DVT can be difficult to detect and may be confused with 
many other conditions.1 It is not an easy diagnosis to make because lots of other conditions mimic 
DVTs, for example lower limb oedema, cellulitis and Bakers cyst. Over 200,000 South Africans suffer 
from DVT each year, because most DVT is occult, the true incidence is unknown. 2 The patients will 
suffer from acute and/or chronic complications such as stasis dermatitis and venous ulcers. While 
the degree of morbidity is significant, mortality rates are equally problematic. Thromboembolic 
disease is annually responsible for 20,000 deaths in South Africa. 3 
1. Pathophysiology of Thrombosis 
There are different theories trying to explain the pathophysiology behind thrombosis. 1, 4 Rudolf 
Virchow, (a German pathologist in the 1800s) defined the types of conditions that could predispose 
patients to abnormal thrombus formation. These categories of risk factors, called "Virchow's triad," 
are1, 4, 5: 
Hypercoagulability 
Venous stasis 
• Endothelial damage. 
i. Hypercoagulable states 
The most common causes of hypercoagulability include mutations in factor V and deficiencies in 
protein C or protein S. Protein C and its cofactor protein S, are Vitamin K-dependent and work 
by inhibiting factors V and VIII. When a deficiency of one of them develops or procoagulation 
factors are not properly inhibited, a tendency for the development of thrombus results. 6, 7 
Deficiencies of antithrombin III and hyperhomocysteinemia are less common genetic causes of 
hypercoagulability.8,9 Pregnancy and the post-partum period are associated with an increased 
risk of DVT due to hypercoagulability. Other causes of hypercoagulability include: Autoimmune 
diseases such as Systemic lupus erythematosus (SLE); 10 Malignancy especially Adenocarcinoma of 
the visceral organs and lung cancer; and medications such as chemotherapy agents and Oestrogens. 
Polycythemia increases the risk for DVT due to an increased haematocrit .11 Obesity has been 
thought in the past to be a unique risk factor for DVT .1,12 Smoking has been associated with an 











ii. Venous stasis 
Any decrease in venous flow, results in stasis of the blood, which predisposes to venous 
thromboembolism for example: immobility, local pressure, congestive heart failure, shock and 
venous obstruction. Immobility implies long trip for more than 6 hours by airplanes, cars or trains 
associated with assuming one position without moving the lower Iimbs.12 There is a clear association 
between the incidence of DVT and the systemic venous pooling seen in Congestive heart failure. 13 
iii. Endothelial damage 
Local damage to the intimal wall of a vein can occur because of inflammation, infection, local 
trauma, or indwelling catheters. However, vessel wall damage is less important in venous 
thrombosis formation than in arterial thrombosis formation. Examples of low-grade chronic vessel 
injury that increase the baseline propensity for thrombosis may include endothelial injury due to 
chemotherapy, hyperhomocysteinemia, vasculitis, or antiphospholipid syndrome. 14 The greatest risk 
factor for venous thrombosis is previous thromboembolic disease. 
Major surgery and mUltisystem trauma often require 2 or more classic risk factors for DVT (e.g. 
activation of clotting factors, immobility and local damage) and together they are responsible for 
up to 40% of all thromboembolic disease. The rate of postoperative DVT in non-anticoagulated 
patients is 70% after non-elective hip surgery, 48% after elective orthopaedic surgery and 12% after 
elective general surgery.1S Upper extremity DVT is far less common than lower extremity DVT and 
is most often associated with the presence of a central venous line. The subclavian vein is the most 
common place to develop upper extremity DVT followed by the axillary and brachial veins. 1s,16 Effort 
thrombosis is a syndrome of DVT unique to the upper extremity, typically occurring in young males 
after strenuous or unusual exercises.16 
2. Risk factors for DVT 
There are numerous recognised risk factors for DVT. The most widely accepted are not discussed in 
detail, but are listed under the clinical decision rule section below. 
i. Clinical Decision Rules 
Here we have defined a clinical decision rule as a clinical tool that quantifies the contributions that 
various components of the patient's history and physical examination make toward the diagnosis. 17 
In 2006, Scarvelis and Wells conducted a comprehensive review of the DVT literature by searching 











examination are poor. The sensitivity of the clinical examination ranges from 60% to 96%, and the 
specificity ranges from 20% to 72%.18 Additionally, they concluded the use of a clinical prediction 
guide that includes specific factors from both the history and physical examination in combination 
with non-invasive tests will simplify diagnosis of patients with suspected DVT. 18 The scoring system 
they developed has become widely known as the Wells score, which enable physicians to reliably 
stratify their patients into high-, moderate-, or low-risk categories. Combining this with the results 
of objective testing greatly simplifies the clinical workup of patients with suspected DVT. Wells 
score is shown in the table. A total score of two or higher indicates that the probability of deep-
vein thrombosis is likely; a total score of less than two indicates that the probability of deep-vein 
thrombosis is unlikely. In patients with symptoms in both legs, use the more symptomatic leg. 18-21 
Wells score is one of the most commonly used criteria to guide further investigations for DVT in 
emergency centres (EC). 22 However, it is not the only one - Landefeld and colleagues23 developed 
another clinical decision rule, but it was based upon a very small sample and its uptake has been 
very poor. It will not be discussed further. The Wells score has never been validated in South Africa. 
Clinical Characteristic Score 
Active cancer (patient receiving treatment for cancer within previous the 6 months or 
1 
currentlv receiving palliative treatment) 
Paralysis, paresis, or recent plaster immobilization of the lower extremities 1 
Recent bedridden for greater than 3 days or major surgery within the previous 12 weeks 
1 
reauiring general or regional anaesthesia 
Localized tenderness along the distribution of the deep venous system 1 
Entire leg swollen 1 
Calf swelling at least 3 cm larger than that on the asymptomatic leg (measured 10 cm below 
1 
tibial tuberosity) 
Pitting oedema confined to the symptomatic leg 1 
Collateral superficial veins (no varicose) 1 
Previously documented deep-vein thrombosis 1 
Alternative diagnosis at least as likely as deep-vein thrombosis -2 
Table: Wells score for DVT risk stratification 18 












According to The Global TB Control Report 2009, the African Region which accounted for an 
estimated 12% of the world population contributed 22% of notified TB cases. Case notification 
rates have increased from 82:100,000 in 1990 to 158:100,000 in 2007 24 Pulmonary tuberculosis 
(PTB) is one of the most prevalent chronic infectious diseases in South Africa and worldwide.25 The 
mortality rate in pulmonary tuberculosis is high in those with advanced disease and in the presence 
of complications. Deep vein thrombosis is reported as a systemic haematological complication in 
patients with PTB. Reactive thrombocytosis, elevations in plasma fibrinogen degradation products 
(FDP), tissue plasminogen inhibitors with depressed antithrombin III levels appear to favour the 
development of DVT in PTB.26 Many studies have also demonstrated that these haematological 
parameters worsen during the first 2 weeks of anti-TB therapy in many cases, but they normalize 
after a month of anti-tuberculosis therapy.27 Thrombosis have been reported in patients with intra-
abdominal lymphadenopathy of tubercular aetiology.28 The high frequency of anti-phospholipid 
antibodies and Protein-S deficiency in patients with tuberculosis is also mentioned in the literature. 28 
Studies have also demonstrated a possible association between DVT and use of Rifampicin 
containing regimens. This does not contraindicate the use of this drug in patients at risk, but such 
patients should be monitored. 29 
Pulmonary tuberculosis is characterized by an acute phase response and leads to a series of 
cellular and molecular interactions that profoundly alter haemostasis .3D One series of patients 
with active pulmonary tuberculosis has shown anaemia, leucocytosis, thrombocytosis, elevation 
in plasma fibrinogen, factor VIII, plasminogen activator inhibitor-1 with depressed antithrombin III 
and protein C levels. Fibrinogen and factor VIII levels had decreased to normal levels, protein C and 
antithrombin III levels had increased to normal levels, and there was no difference in plasminogen 
activator inhibitor-1 levels. None of the patients, however, developed DVT. The hypercoagulable 
state in tuberculosis has been described variously as an increased number of platelets, an increase 
in platelet adhesiveness, hyperfibrinogenemia and a decrease in fibrinolysis. 3D Tuberculosis patients 
have lower levels of anticoagulation factors (protein C, protein S, antithrombin III), with elevation 
in plasma fibrinogen, factor VIII, plasminogen activator inhibitor-1 and D-dimers. White31 found a 
4.7-fold increased incidence of DVT in the rifampicin arm of a study as compared with another anti-
TB regime but could not elucidate the mechanism. In most patients, diagnosis of TB was made 
in the first 2 weeks after admission and start of therapy. Through enzyme induction, rifampicin 
could theoretically alter the balance of procoagulant and anticoagulant proteins produced by 













Infection with the Human Immunodeficiency Virus (HIV) is still a major health problem worldwide. 
According to the latest statistics about HIV/AIDS an estimated 5.6 million people were living 
with HIV and AIDS in South Africa in 2009, more than in any other country. It is believed that in 2009 
an estimated 310,000 South Africans died of AIDS.32 Haematological and vascular complications of 
HIV/AIDS are frequently reported. The incidence was increased two to ten fold in comparison with a 
healthy population of the same age.33 A two- t01O-fold increased incidence of VTE is described in 
HIV-infected patients. 34 An increased risk of venous thrombotic disease in HIV-infected patients 
could be explained by the presence of a hypercoagulable state characterized by an increase in pro-
coagulant factors.35 HIV-infected patients are at increased risk of venous and arterial thrombosis. In 
this Study 35, 109 consecutive HIV-infected patients in the study and tested them twice for currently 
known thrombophilic abnormalities at an interval of at least 3 months (median, 3 months; range, 3-
12 months). After HIV infection was diagnosed, 16% of the patients experienced symptomatic 
thrombosis (venous, 10%; arterial, 6%). Multiple acquired and persistent thrombophilic 
abnormalities are more frequently observed in HIV-infected patients than in the healthy 
population. The frequencies of these thrombophilic abnormalities increase with the progression to 
AIDS. These findings may contribute to the high prevalence of venous and arterial thrombosis in HIV-
infected patients.35 In a case series that described the thrombotic complications of patients infected 
with HIV, it was noted that the patients were characterized by a relatively young age at the time of 
thrombosis, a predominance of elevated levels of lipids, a history of malignancy, and an advanced 
CDC HIV classification, but not by a low CD4 cell count or an elevated HIV load. 35 
3. Diagnosis of DVT 
In addition to the history and physical examination findings as detailed in the Wells score, diagnosis 
of DVT is then dependent upon further testing. Testing is guided by the pre-test probability of DVT, 











expanded upon below. 
i. D-Dimer 
A simple blood test measures the degradation product of factor XIII cross linked fibrin. It reflects 
on-going activation of the haemostatic system. It can be used as rule out test when the pre-test 
probability of DVT is low36, but has little diagnostic yield with an intermediate or high pre test 
probability. 
ii. Duplex Ultrasound 
All other diagnostic measures are imaging based: venography, duplex Ultrasound, CT scan and MRI. 
Venography is traditionally held as the gold standard for evaluating DVT, but it has largely been 
supplanted by duplex venous ultrasonography37 due to its several disadvantages: it is an invasive 
procedure, requires the intravenous injection of contrast, and some patients may develop an allergic 
reaction to the contrast or it may cause nephrotoxicity. Additionally, 2-3% of patients develop DVT 
secondary to venography.38 CT and MRI have reasonable accuracy - although no higher than well 
done ultrasound - but are not affordable in our setting and so are not explored further. 
Duplex Ultrasound consists of evaluating for vein collapsibility under ultrasound transducer 
compression and evaluating blood flow with both colour and spectral Doppler. It is performed 
on the entire proximal deep venous system where accessible. It is an inexpensive, quick and non-
invasive test. Ultrasound can be limited in its utility by the operator's skills and the patient size: in 
obese patients or those with severe lower limb oedema it may be virtually impossible to visualize 
the clot on ultrasound. It has a sensitivity of 95% for proximal DVT, 65% sensitivity for distal DVT, 
and combined specificity of 94%38 ; the diagnosis of distal or calf DVT is frequently difficult and time-
consuming, with sensitivity for isolated calf vein thrombosis in the range of 40-90% 39 Ultrasound 
may however identify a substantial alternative diagnosis, such as a ruptured Baker's cyst, cellulitis 
and presence of hematoma .40 
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MOTIVATION FOR THE STUDY 
The evidence suggests an association between HIV, TB and DVT. There are no studies of this link in 
the Southern African setting, where the incidence of both of these conditions (HIV and TB) is high. 
We therefore undertook a study to define the incidence of HIV and TB in patients with confirmed 
DVT in this setting. 
AIM 
The aim of this study is to describe the incidence of HIV, TB and the more commonly accepted risk 
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To identify the presence of risk factors for DVT in a population of South African public 
healthcare system patients with confirmed DVT. 
2. Methods: 
A retrospective review of patients with ultrasound confirmed DVT at GF Jooste, a Cape Town 
public hospital. Medical notes were reviewed for the presence of established risk factors, TB 
and HIV. 
3. Results 
Eight hundred and sixty five (865) patients with suspected DVT were identified; 685 had 
confirmed DVT. 610 had complete records; 62.6% were female. The location of DVT was 
in lower limbs in 97 % of patients and in upper limbs in 3%. HIV status was positive in 393 
(64.4%), negative in 53 (8.6%) and unknown in 164 (26.8%). TB status was positive in 339 
(55.5%) and negative in the rest. In addition, 264 patients were positive for both HIV and TB; 
135 patients were unknown to have HIV or TB. 
4. Conclusion 
It appears that the risk of developing DVT is high in patients with HIV or TB. More research 
is required to optimally define the risk factors in our population in order to develop a DVT 
scoring system. 
African Relevance: 
• HIV and TB are affecting many patients in this continent. 











Deep vein thrombosis is caused by clot formation in the deep veins of the body. Virchow's Triad 
encapsulates the main pathophysiologic issues in DVT development: hypercoagulable states, venous 
stasis and local damage to the intimal wall of the vein2• Traditionally described risk factors for DVT 
include: immobility, thrombophilia, surgery, pregnancy, recent injury, cancer, congestive heart 
failure, oral contraceptives, previous history of DVT or pulmonary embolism (PE), smoking, advanced 
age and obesity 3. However, there is no literature describing the prevalence of these risk factors in 
patients with DVT the South African context. Recent reports note an increase in the incidence of 
DVT's in H/V positive individuals4; one study showed that thrombotic events are four times more 
common in H/V-infected than the general population, and these occur at a younger ages. Lijfering 
showed that the reasons for this increased rate of thrombosis include protein C and protein F 
deficiency, increased factor VIII and high fibrinogen concentrations6.There is good literature to 
suggest that the occurrence of DVT is much higher in patients with Tuberculosis (TB) infection than 
in the general population7-9• This is thought to be due to the molecular interactions of the acute 
phase response which alter haemostasis, combined with the immobility superimposed with the 
illness8 . TB patients appear to develop a reactive thrombocytosis, elevated plasma fibrinogen levels, 
impaired fibrinolysis and a decrease in antithrombin III, a II of which contribute to thrombogenicity9. 
Diagnosis of DVT 
Well's criteria are internationally accepted as a reliable clinical prediction rule to calculate an 
individual's risk of having a DVT (Table 1) 10. A score of two or higher indicates that the probability of 
a DVT is likely and that further testing is required. However, they have never been validated within 
South Africa; they also exclude two very common and important risk factors: HIV and TB. 
Table 1 near here 
In addition to the role of d-dimer, which is not considered further here, numerous imaging 
modalities can be used to diagnose DVT, including contrast venography, compression and colour 
flow duplex ultrasound, magnetic resonance venography and computed tomographic venographyll. 
Contrast venography is the gold standard, but is time consuming, requires a high degree of technical 
expertise and is invasive. For these reasons, even though ultrasound is less sensitive and specific, it 
has replaced venography as the initial imaging of choicell. Duplex Ultrasound consists of evaluating 
for vein collapsibility under ultrasound transducer compression and evaluating blood flow with 












Ultrasound has a reported sensitivity of 95% for proximal and 65% for distal DVT, and a specificity 
of 94%12 (although some studies claim a sensitivity for diagnosis of isolated calf vein thrombosis 
between 40-90%14).lt is a relatively inexpensive, quick and non-invasive test, but is limited by the 
operator's skills and the patient size (in obese patients or those with severe lower limb oedema it 
may be virtually impossible to visualize the clot on ultrasound). The diagnosis of distal or calf DVT is 
frequently difficult and time-consuming with ultrasound13, 14; but a significant alternative diagnosis, 
such as a ruptured Baker's cyst, cellulitis or haematoma may easily be diagnosed using ultrasound. is, 
161n South Africa, duplex ultrasound is the most commonly utilized test to evaluate for the presence 
of DVT: confirmation of DVT is determined by a positive compression and/or colour flow duplex 
ultrasound. 
Given the lack of locally relevant information on the relationship between DVT and HIV and TB, we 
undertook a study to describe the incidence of these 2 risk factors in patients with DVTs in a South 
African population. 
METHODS 
GF Jooste is a busy urban 224 bed district hospital situated in one of the city's most violent township 
areas. It has a high rate of HIV and TB in its patient catchment area. It runs an emergency centre 
which sees around 40,000 patients per year. 
We retrospectively reviewed medical records of all patients with a confirmed DVT presenting to 
the ultrasound department of GF Jooste hospital, Cape Town from 1 April 2008 to 30 April 2011. 
The ultrasound registers were reviewed by the primary researcher, to identify patients undergoing 
ultrasound for suspected DVT. All such patients were reviewed and those with positive findings were 
identified and formed the study population. 
Medical records were retrieved on all patients with positive scans; patients with missing or 
incomplete records were excluded from the analysis. A standardized data capture form was used to 
collect age, sex, site of DVT (upper or lower limbs), risk factors for DVT, HIV status (positive, negative 
or unknown) and TB status (positive, negative). Data were entered into a Microsoft Excel 2010 
(© Microsoft, Richmond VA) spread sheet and data analysed using Stata 10 (©Statacorp, College 
Station, Tx). 













Eight hundred and sixty-five patients with suspected DVT were identified from the ultrasound 
register during the study period: 685 had confirmed DVT. Of these, 610 had available medical 
records of DVT, 48 records were missing and 27 records were conflicting and therefore unusable. 
Therefore the total study sample was 610 patients. 
Figure near here 
The median age for the group was 37 years (interquartile range 15 - 88 years). Of the patients who 
had DVT, 62.6% were female. The location of DVT was in lower limbs in 97 % (male 95%, female 
99%); all others occurred in the upper limbs. 
HIV stats was recorded as positive in 393 (64.4%), negative in 53 (8.6%) and unknown in 164 (26.8%); 
TB status was positive in 339 (55.5%). A total of 264 patients were both HIV and TB positive; 137 
patients were not known to have HIV or TB. Table 2 contains details of other commonly identified 
risk factors in this population. 
Table 2 near here 
DISCUSSION 
We conducted this descriptive study trying to find the commonest risk factors of DVT among the 
South African population and to show the possible association between HIV and TB, as independent 
risk factors of DVT. South Africa ranks fourth in the world in terms of absolute TS cases after India, 
China and Indonesia. TB is the most common opportunistic infection in HIV infected people. 17 
Approximately 5.6 million South Africans were living with HIV in 2009 of which roughly 1 million 
people are currently accessing antiretroviral treatment.18 The prevalence of HIV in South Africa is 
currently between 11% and 19%.19 The HIV epidemic in South Africa has a significant impact on the 
burden of tuberculosis. TB notification rates have increased to 1500 / 100000 populations more 
commonly in poverty stricken areas.20 
GF Jooste Hospital currently provides district and regional services to more than 1 million people. 
This population presents a good sample of the South African population with different races and 
age groups. A 2003 survey of medical admissions to GF Jooste hospital showed that approximately 
32.3% of surveyed patients were HIV positive and most of them (85.2%) had WHO Stage III disease 
or AIDS. 21 With regards to the tuberculosis-related burden of disease, 20.6% of surveyed patients 












Our findings clearly show that in most cases of DVT the patient is HIV positive or has TB or both. 
More than 64% had HIV and more than 55% had TB: 43.2% were positive for both HIV and TB. This 
suggests a clear association between both of these conditions and the development of DVT. 
Nearly two thirds of patients were female: this is not representative of the EC population, which 
is closer to half female. Only 14 of these patients were pregnant, but insufficient other clinical 
information were captured to allow deductions to be made as to why this female predominance is 
seen. 
Upper limb DVT was found in 3%: all of them were secondary to previous central line insertion. 
The commonest "traditional" risk factors for DVT were immobility and history of previous DVT / PE 
(8.7%,4.3% respectively). History of cancer, CCF and obesity were found in 3-4% of patients. 
LIMITATIONS 
As this is a retrospective records review including only patients identified from the ultrasound. This 
study is limited by the documented patient information and work-up done by the managing medical 
staff. As such it is expected that there may be occasions when risk factors and/or comorbidities have 
not been accurately recorded. Therefore our reported incidence rates may be at the lower end of 
the real rates. 
Some records were not available at the time of review. This could have affected the incidence rate in 
either direction. However, there is no reason to suppose that the 11% missing records were different 
in any way to the records retrieved. 
The use of ultrasound as diagnostic measure also has its limitations, as it is not the gold standard for 
the diagnosis of DVT. However, it is standard practice in most countries today, and has performance 
characteristics suitable to allow reasonable interpretation of its results. 
The study was conducted at one centre (GF Jooste hospital) in the Western Cape and may not reflect 
the results in different centres. 
CONCLUSION 
This is the first study reporting the incidence of HIV and TB in patients with DVT in a South African 
setting. We have demonstrated a very high rate of infection with either of both pathogens in this 
population. More research is required to determine whether this association is repeated in other 
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Table 1: Wells Clinical Model for Predicting Pre-test Probability for DVT 10 
CLINICAL CHARACTERISTIC SCORE 
Active cancer (patient receiving treatment for cancer within previous the 6 months or 
1 
currently receiving palliative treatment) 
Paralysis, paresis, or recent plaster immobilization of the lower extremities 1 
Recent bedridden for greater than 3 days or major surgery within the previous 12 weeks 
1 
requiring general or regional anaesthesia 
Localized tenderness along the distribution of the deep venous system 1 
Entire leg swollen 1 
Calf swelling at least 3 cm larger than that on the asymptomatic leg (measured 10 cm below 
1 
tibia tuberosity) 
Pitting oedema confined to the symptomatic leg 1 
Collateral superficial veins (no varicose) 1 
Previously documented deep-vein thrombosis 1 











Table 2: Risk factors for DVT 
RISK FACTORS n (%) 
HIV 393 {64.43} 
rB 339 (55.57) 
IMMOBILITY 53 {B.69} 
PREVIOUS DVT /PE 26 {4.26} 
CANCER 25 (4.1O) 
CCF 22 {3.61} 
OBESITY 19 {3.11} 
RECENT SURGERY 3 {0.49} 
PREGNANCY 14 {2.30} 
TRAUMA 10 {1.64} 
SMOKING 11 (LBO) 
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It is estimated that over 200,000 South Africans suffer from deep vein thrombosis (DVT) 
each year, but because DVT is occult the true incidence is unknown(. 
Deep vein thrombosis is caused by thrombus formation in the deep veins of the body. 
Virchow's Triad describes the risk factors for DVT to include hypercoagulable states, 
venous stasis and local damage to the intimal wall ofthe vein 2• 
Traditional risk factors for DVT include: immobility, thrombophilia, surgery, pregnancy, 
recent injury, cancer, congestive heart failure, oral contraceptives, previous history of 
DVT or PE (pulmonary embolismL smoking, age and obesity3. No literature describes the 
prevalence of the aforementioned risk factors for DVT in the South African population. 
More recently an increase in the incidence of DVT's in patients with HIV (Human 
immunodeficiency virus) has been described4 with one study showing that thrombotic 
events are four times more common in HIV-infected individuals than the general 
population and occur among these HIV infected patients despite their younger ageS, 
Lijfering et al6 showed that reasons for this increased incidence of thrombosis included 
protein C and protein F deficiency, increased factor VIII concentrations and high 
fibrinogen concentrations. 
There is also literature supporting the occurrence of DVT in patients with Tuberculosis 
(TB) infection?' 8, and 9. This is thought to be due to the molecular interactions of the acute 
phase response that alters haemostasis combined with the immobility superimposed 
with the illness8 . These changes that occur in patients with TB appear to include a 
reactive thrombocytosis, elevated plasma fibrinogen with impaired fibrinolysis and a 
decrease in antithrombin 1119. 
Well's criteria for DVTlo is an internationally accepted clinical prediction tool to 
calculate an individual's risk of having a DVT. A score of two or higher indicates that the 
r''''~'-
probabilityof a DVT is likely and that further tes~i.l1~ is reCll:lir~~~ 
IWelis et al Clinical Model For Predicting Pre-test Probability For DVT 10 
I 
i ! ............................... . 
!Clinical Characteristic Score 
i········· .... · .. ······•······· .. ·· .. ··· .. ·· .. · .. ···~··· .. ·••• .. ..................... . 
!Active cancer (patient receiving treatment for cancer within previous the 6 months or1 
!currently receiving palliative treatment) 
l·· ...... ~········· 
\Paralysis, paresis, or recent plaster immobilization of the lower extremities 1 
I~ecent bedridden for greater than 3 days or major surgery within the previous 12 weeks1 
Irequiring general or regional anesthesia 
I 
r"AA>~~ ," 
!Localized tenderness along the distribution of the deep venous system 1 
t ,w,.w, 'w_~,~ ,,~"'m~~" 'W'''", ," , ", "w'wW" 
!Entire leg swollen 1 
I ........ ~ ... ~ ....... . 
Icalf swelling at least 3 cm larger than that on the asymptomatic leg (measured 10 cm below1 
!tibia tuberosity) 
t············ 
!Pitting edema confined to the symptomatic leg 1 
Icollateral superficial veins (no varicose) 1 
r"' 
IPreviously documented deep-vein thrombosis 1 
r'.w,,~"'~'''w 













Well's criteria has never been validated within South Africa and also excludes the 2 
independent risk factors which affects the South African population and which this study 
is looking at, namely HIV and TB. 
There are numerous modalities available that can be used to diagnose DVT. These 
modalities include: contrast venography, compression and colourflow duplex 
ultrasound, magnetic resonance venography and computed tomographic venographyll. 
Contrast venography is the gold-standard, but is time consuming, requires a high degree 
of technical expertise and is invasive. For these reasons, even though ultrasound is 
less sensitive and specific, it has replaced venography as the initial imaging of choice ll. 
For this study, confirmation of the presence of DVT shall be determined by a positive 
compression and/or colour flow duplex ultrasound. 
1.2. Aim 
The aim of this study is to describe the risk factors present in patients with deep vein 
thrombosis in a Western Cape Hospital population 
1.3. Objectives 
1.3.1. To evaluate what traditional risk factors for DVT are present in Western Cape 
patients with ultrasound confirmed Deep Vein Thrombosis. 
1.3.2. To evaluate the presence of HIV and/or TB in Western Cape patients with 
ultrasound confirmed DVT. 
2. Methods 
36 
2.1. Study design 
This will be a retrospective descriptive study. A review of the ultrasound registers 
over a 36 month period at GF Jooste will be done. All patients who have undergone 
ultrasound by sonographers and/or radiologists for suspected DVT will be reviewed 
and those with positive findings will be identified. Folders will then be requested for 
those patients with ultrasound confirmed DVTs. The data capture sheet will then be 
filled in using the information gained from the patients' folders. The names of the 
patients will not be kept, only the information from the files will be stored with study 
numbers (not folder numbers). 
2.2. Study population 
The ultrasound registers over a 36 month period at GF Jooste Hospital will be 
reviewed for patients undergoing ultrasound for suspected DVT. Those patients 
with positive findings will form the study population. It is estimated that the study 
population will be approximately 550 patients. 
2.3. Sampling 










All patients with deep vein thrombosis as identified by ultrasounds done by 
sonographers and/or radiologists over a 36 month period at the above hospital will 
form the study population. 
2.3.2. Exclusion criteria 
Patients under the age of 18 will be excluded from the study. Patients whose folders 
are missing will be excluded from the study population. 
2.4. Data collection and management 
The primary investigator shall request the folders of those patients with positive 
DVTs. The primary investigator shall then complete the data capture sheet using 
only study numbers and not folder numbers or any other identifying characteristics. 
The data capture sheets shall then be entered into a password protected computer 
and stored by the primary investigator. 
2.5. Timeline 
Ethics Mar 2012, Data Capturing April 2012, Write up May 2012 
3. Statistical analysis 
Data will be collated in a Microsoft Excel database. Statistical analysis will be done with 
the help of UCT statisticians. Simple descriptive statistics (means and medians and 
standard deviations) will be used to describe the demographic data. The assistance of 
a statistician will be sought to determine potential statistical associations between key 
variables. 
4. Ethical and legal considerations 
This will be a retrospective folder review. The data collected will be anonymous. The 
folder numbers will initially be used to track data information, but thereafter no patient 
identifying characteristics will be recorded. Only the primary researcher will have access 
to patients' folders and data sheets while recording the information. All patients will 
only be identified by study numbers. These study numbers will not be cross referenced 
with patient's names or folder numbers. Patient consent will not be required as the 
study does not involve any intervention or recording of patient details. 
This study will seek approval from the University of Cape Town Ethics Committee. 
Furthermore, permission for access to ultrasound records and patient medical records 
will be obtained from the above listed hospital administrator and the Provincial 
Department of Health. 
5. limitations 
As this is a folder review, this study will be limited by the patient information recorded 
and workup done by the medical staff that managed the patient. As such it is expected 
that there may be many occasions when all risk factors and/or comorbidities have not 













Printing costs 40 x SOc R 20.00 
Transport costs R 500 
Total Rs20 
The study will be funded by the researcher. 
7. Reporting and implementation of results 
The results of this study will be written up and submitted to a peer reviewed journal for 
publication for dissemination of information of risk factors for DVT in the South African 
population. 
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APPENDIX B: DATA COLLECTION SHEET 
Study Demo- Site ofDVT 
No graphics Risk factors for DVT 
R= Right C P R P I C T T S 0 
L = Left an r e r m 0 r h m b 
F = Femoral c e c e m n a r 0 e 
P = Popliteal HIV TB er v e g 0 g u 0 k s 
I = Iliac (0 I n n b e m m i I 
S = Subclavian ng 0 t a 1 s a b n t Other 
Ag Se (If other site, then site 01 u s n 1 t 0 g y 
e x to be recorded) ng s u c I I 0 P 
or r y t v r h 
WI D g Y e f I 
th V e r 1 
in T r h a I 
6 Y e c a 
m 0 a t 
on r r u 
th P t r 






















CODE USED FOR RISK FACTORS WHILE DATA CAPTURING: 











N = No (Recorded in notes as not being present - as a negative finding) 
U = Unknown (Not recorded as being present or absent - so unknown) 
S = Suspected (When the condition was suspected by the treating clinicians, but not confirmed. This may occur for example in HIV infection 
when the patient refused testing) 
44 
